Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
New study sits at the center of this dementia and brain health question.
Recent research confirms what many in dementia care have come to realize: Alzheimer’s disease progression is not inevitable. A growing body of evidence shows that with the right combination of medical treatments and lifestyle interventions, it is possible to slow cognitive decline, preserve memory function, and maintain quality of life for longer. The question is no longer whether Alzheimer’s can be managed—it’s how to implement these strategies effectively for the people who need them most.
The breakthrough comes from multiple directions at once. New anti-amyloid monoclonal antibody drugs have demonstrated significant efficacy in slowing cognitive decline in early-stage Alzheimer’s disease. Simultaneously, rigorous studies have quantified the protective power of preventive behaviors, showing that adherence to healthy lifestyle practices can reduce Alzheimer’s risk by as much as 60 percent. For the first time, families and caregivers have concrete options to discuss with their doctors—options that extend beyond memory care to active disease modification.
Table of Contents
- What Do Recent Studies Show About Slowing Alzheimer’s Progression?
- The Drug Revolution in Alzheimer’s Treatment: How Anti-Amyloid Antibodies Work
- Building Protection Before Disease Appears: The Power of Lifestyle Intervention
- Specific Interventions That Show Promise: Beyond Exercise and Diet
- Understanding and Managing the Risks of Anti-Amyloid Immunotherapy
- The Importance of Early Detection and Diagnosis
- Looking Forward: What the Convergence of Evidence Means for Dementia Care
- Conclusion
What Do Recent Studies Show About Slowing Alzheimer’s Progression?
The clinical evidence for disease-modifying treatments has become compelling. Lecanemab and donanemab, both anti-amyloid monoclonal antibodies, have shown measurable benefits in reducing cognitive decline in early Alzheimer’s disease. These drugs work by targeting amyloid accumulation in the brain—the buildup of protein that is believed to damage and destroy nerve cells. In clinical trials, people receiving these treatments experienced improvements in memory, cognitive function, and ability to perform daily living tasks compared to those on placebo. The effects are not dramatic transformations, but rather meaningful preservation of cognitive abilities that would otherwise have declined. Long-term data from the TRAILBLAZER-ALZ 2 trial demonstrates that donanemab’s benefits persist over years, not months.
More than 75 percent of participants achieved amyloid clearance within 76 weeks, and this improvement held through up to three years of follow-up. This is significant because it means the treatment addresses a fundamental biological problem in the disease rather than simply masking symptoms temporarily. For people diagnosed in the mild cognitive impairment or mild dementia stages, having access to a disease-modifying drug represents a genuine departure from previous options. A major practical advance came in 2025 when the FDA approved a weekly subcutaneous maintenance dosing formulation of lecanemab. This means that after an initial 18-month course of intravenous infusions, patients can transition to self-administered injections at home—a significant improvement in convenience and quality of life compared to frequent hospital or clinic visits. However, these medications are not right for everyone, and they carry risks that must be carefully weighed and monitored.
The Drug Revolution in Alzheimer’s Treatment: How Anti-Amyloid Antibodies Work
Anti-amyloid monoclonal antibodies represent a fundamental shift in how medicine approaches Alzheimer’s disease. Rather than treating symptoms like memory loss or confusion, these drugs target the biological cascade that drives neurological damage. Amyloid-beta proteins misfold and accumulate in the brains of people with Alzheimer’s disease, forming plaques that are believed to trigger inflammation and the death of nerve cells. Lecanemab and donanemab work by binding to these amyloid aggregates and facilitating their removal from the brain. What makes these drugs effective is their specificity combined with their measurable impact on disease biomarkers. In imaging studies, doctors can literally see amyloid clearing from the brain in people receiving these treatments.
The cognitive benefits follow this biological change—as amyloid levels drop, the rate of cognitive decline slows. For someone in the early stages of Alzheimer’s disease, slowing the rate at which they lose memory or cognitive ability can mean years of additional functional independence. A person who might have progressed from mild cognitive impairment to moderate dementia in three years might instead take five or six years with treatment, extending the window in which they can drive, manage finances, live independently, or remain actively involved in family life. The limitation important to understand is that these drugs work best when disease is caught early—specifically in people with amyloid biomarker evidence of brain changes but who still have mild cognitive symptoms. They are less effective in people with advanced dementia and no evidence of amyloid pathology. Additionally, while they slow decline, they do not stop it or reverse it. Someone on these medications will continue to experience some cognitive changes; the benefit is relative, not absolute.
Building Protection Before Disease Appears: The Power of Lifestyle Intervention
While pharmaceutical breakthroughs capture headlines, the research on preventive behaviors may ultimately have the broadest impact. A major 2025 NIH study quantified something that gerontologists have long suspected: adherence to healthy lifestyle practices dramatically reduces Alzheimer’s risk. People who maintained four or five specific healthy behaviors—not smoking, limiting alcohol consumption, eating a high-quality diet, engaging in regular cognitive activities, and exercising for at least 150 minutes per week at moderate to vigorous intensity—had a 60 percent lower risk of developing Alzheimer’s disease compared to those who followed none or only one of these behaviors. Even moderate adherence matters. People who followed two or three of these behavioral practices had a 37 percent reduction in Alzheimer’s risk. This finding has profound implications because it means prevention is not an all-or-nothing proposition.
A person who cannot currently manage all five behaviors can still gain significant protective benefit from improving in several areas. For families with a history of dementia, these behavioral targets give them concrete, actionable steps. Unlike genetic risk factors that cannot be changed, lifestyle factors are directly within a person’s control. The practical challenge is that sustained behavior change is difficult, particularly for people managing other chronic diseases, financial constraints, or limited access to safe spaces for exercise. An 80-year-old living in a cold climate with limited transportation may struggle to maintain 150 minutes of weekly physical activity. A person with limited income may find a high-quality diet unaffordable. Success often requires support from family members, community resources, or healthcare providers who can help problem-solve around individual barriers.
Specific Interventions That Show Promise: Beyond Exercise and Diet
Several specific interventions have emerged from recent research as deserving attention for their measurable cognitive benefits. The ACHIEVE Study demonstrated that fitting older adults with hearing aids reduced the rate of cognitive decline by nearly 50 percent in people with hearing loss and specific dementia risk factors. This finding was surprising to many clinicians because it revealed an unexpected link between hearing and brain health—one mechanism appears to be that untreated hearing loss increases cognitive load as the brain works harder to interpret degraded auditory information. For someone with both hearing loss and cognitive concerns, addressing the hearing problem becomes not just about conversation quality but about preserving brain function. A modified Mediterranean ketogenic diet has shown biochemical promise in early-stage research. After just six weeks of consuming this dietary pattern, participants showed significant changes in blood and spinal fluid biomarkers—specifically increases in beneficial cholesterol and reductions in body mass index and systemic inflammation.
While longer-term studies on cognitive outcomes are still underway, the biomarker changes suggest the diet may help address some of the inflammatory processes involved in neurodegeneration. This represents an example of how dietary interventions can move beyond general health advice to target specific biological mechanisms related to dementia risk. Cognitively enriched tai chi offers another example of an accessible intervention that showed cognitive benefits in clinical trials. In people with mild cognitive impairment, cognitively enriched tai chi—a version designed to include memory and attention challenges alongside physical movement—was superior to standard tai chi in improving global cognition. The benefits persisted when participants were reassessed 48 weeks later. The advantage of tai chi compared to other exercise forms is that it combines physical activity with cognitive stimulation and can be practiced safely even by people with balance problems or joint issues.
Understanding and Managing the Risks of Anti-Amyloid Immunotherapy
The same mechanism that makes anti-amyloid antibodies effective—removing amyloid from the brain—carries a significant safety risk that must be openly discussed. These medications carry a 4.35 times higher relative risk of developing amyloid-related imaging abnormalities (ARIA) compared to control groups. ARIA includes two main types: microhemorrhages (small bleeds in the brain) and microinfarcts (small areas of dead brain tissue). In some cases, patients develop white matter changes or superficial siderosis, a condition involving iron accumulation on the brain’s surface. These risks are not theoretical or rare side effects relegated to a small print warning. In clinical trials, ARIA occurred in roughly 20 to 35 percent of people receiving anti-amyloid antibodies, depending on the specific drug, dose, and patient characteristics. The presence of the APOE4 gene—a genetic risk factor for Alzheimer’s disease—increases the risk substantially.
Most people with ARIA experience no symptoms, and the condition is detected only through periodic MRI scans. However, some people experience symptoms including headaches, vision changes, confusion, or neurological symptoms. In rare cases, microhemorrhages can be serious. Because of these risks, doctors typically recommend regular MRI monitoring while people take these medications. They also tend to be cautious about offering these drugs to people at very high risk for ARIA or those who would have difficulty managing the monitoring requirements. This creates a practical limitation: a person who would most benefit from these medications—someone at very early disease stages with strong biomarker evidence of Alzheimer’s pathology—is often the same person who needs to make a careful shared decision about whether the risk of ARIA is worth the benefit of slowing cognitive decline. This is not a decision to make lightly or in isolation; it requires thoughtful discussion with a neurologist or dementia specialist who understands both the person’s individual risk factors and their values and priorities.
The Importance of Early Detection and Diagnosis
Managing Alzheimer’s progression effectively depends critically on early identification. The most effective interventions—whether pharmaceutical or lifestyle-based—work best when disease is caught in its earliest stages, before substantial neuronal damage has occurred. This creates a role for cognitive screening and biomarker testing that goes beyond traditional dementia evaluation.
Someone who complains of occasional memory difficulties or whose family notices subtle changes in cognition deserves comprehensive evaluation, not reassurance that “everyone forgets things sometimes.” Blood tests for Alzheimer’s biomarkers have become increasingly accurate and accessible. Tests measuring phosphorylated tau and amyloid-beta levels can identify people with Alzheimer’s pathology even before cognitive symptoms become obvious. For someone with a family history of dementia, or anyone experiencing cognitive concerns, asking their doctor about biomarker testing represents a proactive approach. Early detection opens the window for preventive interventions and disease-modifying treatments during the years when they are most likely to help.
Looking Forward: What the Convergence of Evidence Means for Dementia Care
The emerging picture of Alzheimer’s management is not one of a single magic bullet but rather multiple complementary approaches. Some people will benefit from pharmaceutical interventions like lecanemab or donanemab. Others will see greatest benefit from committing to the behaviors shown to prevent dementia—exercise, cognitive engagement, healthy diet, hearing correction, and social connection.
Most people will likely benefit from a combination: optimizing modifiable risk factors while considering whether disease-modifying drugs are appropriate for their specific situation. What these advances share is a fundamental message: Alzheimer’s disease is not a fate to be passively accepted. For the first time, people at risk, people with early symptoms, and their families have concrete options to discuss with healthcare providers. The question has shifted from “What can we do?” to “What combination of approaches is right for this person, given their individual circumstances, risk factors, and values?” This represents genuine progress in how medicine approaches one of the most feared diseases of aging.
Conclusion
Recent research demonstrates conclusively that Alzheimer’s disease progression can be managed through a combination of pharmaceutical and lifestyle interventions. Drug treatments like lecanemab and donanemab slow cognitive decline in early-stage disease, while maintaining healthy behaviors—exercise, cognitive engagement, quality diet, hearing correction, and limited alcohol use—can reduce dementia risk by 37 to 60 percent depending on the number of behaviors adopted. These advances offer families and individuals the opportunity to take active steps rather than face a predetermined outcome.
The practical next step is to talk with a healthcare provider about individual risk factors, available screening options, and which interventions might be most appropriate. For someone concerned about cognitive changes or dementia risk, this might mean requesting biomarker testing to understand their disease status. For others, it means committing to the behavioral practices proven to lower risk. The pathway forward is different for each person, but the direction is clear: Alzheimer’s progression can be addressed, managed, and slowed.
You Might Also Like
- New Study Suggests Alzheimer’s Risk Starts in Midlife
- New Study Suggests Alzheimer’s May Be Preventable in Some Cases
- New Study Claims Alzheimer’s May Begin Decades Before Diagnosis
For more, see Alzheimer’s Association — medical tests.
